Patents by Inventor Vivienne S. Marshall
Vivienne S. Marshall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10286015Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: April 25, 2017Date of Patent: May 14, 2019Assignee: Noveome Biotherapeutics, Inc.Inventors: George L Sing, Vivienne S Marshall
-
Publication number: 20170224740Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: April 25, 2017Publication date: August 10, 2017Applicant: Noveome Biotherapeutics, Inc.Inventors: George L Sing, Vivienne S. Marshall
-
Patent number: 9173908Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: February 5, 2015Date of Patent: November 3, 2015Assignee: STEMNION, INC.Inventors: Richard A. Banas, Catherine J. Trumpower, Vivienne S. Marshall
-
Patent number: 9138443Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: July 16, 2013Date of Patent: September 22, 2015Assignee: STEMNION, INC.Inventors: Richard A Banas, Vivienne S Marshall, Catherine J Trumpower
-
Publication number: 20150202235Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: ApplicationFiled: November 20, 2014Publication date: July 23, 2015Applicant: Stemnion, Inc.Inventors: Charlotte A. Emig, Vivienne S. Marshall
-
Patent number: 9084787Abstract: The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: March 11, 2013Date of Patent: July 21, 2015Assignee: STEMNION, INC.Inventors: George L Sing, Diana L Clarke, Vivienne S Marshall
-
Publication number: 20150147358Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: February 5, 2015Publication date: May 28, 2015Applicant: Stemnion, Inc.Inventors: Richard A. Banas, Catherine J. Trumpower, Vivienne S. Marshall
-
Patent number: 8877181Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: November 4, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S Marshall, Richard A Banas
-
Patent number: 8871198Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: March 14, 2007Date of Patent: October 28, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
-
Patent number: 8808753Abstract: The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.Type: GrantFiled: March 6, 2013Date of Patent: August 19, 2014Assignee: Stemnion, Inc.Inventors: Linda O Palladino, Vivienne S Marshall, Charlotte A Emig
-
Patent number: 8796025Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: May 8, 2012Date of Patent: August 5, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
-
Patent number: 8741646Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 6, 2011Date of Patent: June 3, 2014Assignee: Stemnion, Inc.Inventors: Charlotte A Emig, Vivienne S Marshall
-
Patent number: 8709402Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: April 29, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S Marshall
-
Patent number: 8685390Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: April 1, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S. Marshall
-
Patent number: 8647617Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: May 30, 2012Date of Patent: February 11, 2014Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Richard A. Banas, Catherine J. Trumpower
-
Publication number: 20140017193Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: September 17, 2013Publication date: January 16, 2014Applicant: Stemnion, Inc.Inventors: George L. Sing, Vivienne S. Marshall
-
Publication number: 20130302289Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: July 16, 2013Publication date: November 14, 2013Inventors: Richard A. Banas, Vivienne S. Marshall, Catherine J. Trumpower
-
Patent number: 8530418Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: October 17, 2012Date of Patent: September 10, 2013Assignee: Stemnion, Inc.Inventors: Vivienne S Marshall, Catherine J Trumpower, Charlotte Emig
-
Patent number: 8506949Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: May 30, 2012Date of Patent: August 13, 2013Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Richard A. Banas, Catherine J. Trumpower
-
Patent number: 8475788Abstract: The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: November 27, 2007Date of Patent: July 2, 2013Assignee: Stemnion, Inc.Inventors: George L. Sing, Diana L. Clarke, Vivienne S. Marshall